PRECIGEN, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PRECIGEN, INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- PRECIGEN, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $30.88M.
- PRECIGEN, INC. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00.
- PRECIGEN, INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $0.00.
- PRECIGEN, INC. stock issued during period, value, new issues for fiscal 2024 was $30.88M, a 57.58% decline from fiscal 2023.
- PRECIGEN, INC. stock issued during period, value, new issues for fiscal 2023 was $72.81M.
- PRECIGEN, INC. stock issued during period, value, new issues for fiscal 2021 was $121.05M, a 245.84% increase from fiscal 2020.
- PRECIGEN, INC. stock issued during period, value, new issues for fiscal 2020 was $35.00M, a 429.42% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $30.88M 10-K · filed 2026-03-25 |
| 2024-09-30 | $30.88M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $72.81M 10-K · filed 2026-03-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-06-30 | $27.00K 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $72.78M 10-Q · filed 2024-05-14 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $121.05M 10-K · filed 2024-03-19 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $121.05M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $121.05M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $121.05M 10-Q · filed 2022-05-09 | $121.05M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $35.00M 10-K · filed 2023-03-06 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $35.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $35.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $35.00M 10-Q · filed 2021-05-10 | $35.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $6.61M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $6.61M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $6.61M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $6.61M 10-Q · filed 2020-05-11 | $6.61M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $87.99M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | |
| 2018-03-31 | $87.99M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $13.69M 10-K · filed 2020-03-02 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $328.23M 10-K · filed 2018-03-01 |
| 2015-09-30 | $218.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $328.23M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $110.04M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $110.04M 10-Q · filed 2015-05-11 | $110.04M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $25.00M 10-K · filed 2017-03-01 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $25.00M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | |
| 2014-03-31 | $25.00M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $168.80M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |